Teva Pharma (TEVA) Reports Health Canada Approves Application for Generic Cipralex

Go back to Teva Pharma (TEVA) Reports Health Canada Approves Application for Generic Cipralex

Teva Pharma (TEVA) Reports GLACIER Study Primary Endpoint Achieved

September 11, 2014 9:30 AM EDT

Teva Pharma (NYSE: TEVA) announced new data from the open-label Phase IIIb GLatiramer Acetate low frequenCy safety and patIent ExpeRience (GLACIER) study, comparing the safety and tolerability of three-times-a-week COPAXONE® (glatiramer acetate injection) 40 mg to daily COPAXONE® 20 mg in patients with relapsing-remitting multiple sclerosis (RRMS). During a platform presentation this week, the results from the GLACIER study were shared at the MS Boston 2014: Joint ACTRIMS-ECTRIMS Meeting being held in Boston, Massachusetts.

The primary endpoint of the GLACIER study, the adjusted mean annualized rate of injection-related... More